News for Galectin Therapeutics Stock (GALT)

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

GlobeNewsWire • 04/27/23

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

GlobeNewsWire • 04/18/23

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

GlobeNewsWire • 03/30/23

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

GlobeNewsWire • 03/16/23

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

GlobeNewsWire • 01/24/23

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

GlobeNewsWire • 01/05/23

Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now

Zacks Investment Research • 12/13/22

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

GlobeNewsWire • 11/28/22

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

GlobeNewsWire • 11/14/22

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

GlobeNewsWire • 11/01/22

Galectin Therapeutics to Present in Upcoming Conferences

GlobeNewsWire • 10/14/22

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

GlobeNewsWire • 10/12/22

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

GlobeNewsWire • 10/06/22

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

GlobeNewsWire • 09/08/22

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

GlobeNewsWire • 08/15/22

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

GlobeNewsWire • 07/26/22

Galectin: Ability To Potentially Target Unmet Medical Need

Seeking Alpha • 07/11/22

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

GlobeNewsWire • 06/21/22

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

GlobeNewsWire • 05/23/22

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

GlobeNewsWire • 05/16/22

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

GlobeNewsWire • 04/14/22

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

GlobeNewsWire • 03/31/22

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

GlobeNewsWire • 01/06/22

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

GlobeNewsWire • 12/21/21

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

GlobeNewsWire • 12/13/21